Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: The influence of hydrogen bond donors on extravascular transport and antitumor activity

被引:38
作者
Hay, Michael P. [1 ]
Pchalek, Karin [1 ]
Pruijn, Frederik B. [1 ]
Hicks, Kevin O. [1 ]
Siim, Bronwyn G. [1 ]
Anderson, Robert F. [1 ]
Shinde, Sujata S. [1 ]
Phillips, Victoria [1 ]
Denny, William A. [1 ]
Wilson, William R. [1 ]
机构
[1] Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Society Res Ctr, Auckland 1142, New Zealand
关键词
D O I
10.1021/jm701037w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tirapazamine (TPZ) and related 1,2,4-benzotriazine 1,4 dioxides (BTOs) are selectively toxic under hypoxia, but their ability to kill hypoxic cells in tumors is generally limited by their poor extravascular transport. Here we show that removing hydrogen bond donors by replacing the 3-NH2 group of TPZ with simple alkyl groups increased their tissue diffusion coefficients as measured in multicellular layer cultures. This advantage was largely retained using solubilizing 3-alkylaminoalkyl substituents provided these were sufficiently lipophilic at pH 7.4. The high reduction potentials of such compounds resulted in rates of metabolism too high for optimal penetration into hypoxic tissue, but electron-donating 6- and 7-substituents moderated metabolism. Pharmacokinetic/pharmacodynamic model-guided screening was used to select BTOs with optimal extravascular transport and hypoxic cytotoxicity properties for evaluation against HT29 human tumor xenografts in combination with radiation. This identified four novel 3-alkyl BTOs providing greater clonogenic killing of hypoxic cells than TPZ at equivalent host toxicity, with the 6-morpholinopropyloxy-BTO 22 being 3-fold more active.
引用
收藏
页码:6654 / 6664
页数:11
相关论文
共 47 条
[1]   Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction [J].
Anderson, RF ;
Shinde, SS ;
Hay, MP ;
Gamage, SA ;
Denny, WA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (03) :748-756
[2]  
Baguley BC, 2002, ANTICANCER DRUG DEV, P269
[3]   SR-4233 (TIRAPAZAMINE) - A NEW ANTICANCER DRUG EXPLOITING HYPOXIA IN SOLID TUMORS [J].
BROWN, JM .
BRITISH JOURNAL OF CANCER, 1993, 67 (06) :1163-1170
[4]  
Brown JM, 1998, ANTI-CANCER DRUG DES, V13, P529
[5]   Exploiting tumour hypoxia in cancer treatment [J].
Brown, JM ;
William, WR .
NATURE REVIEWS CANCER, 2004, 4 (06) :437-447
[6]  
Brown JM, 1998, CANCER RES, V58, P1408
[7]   Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma [J].
Cairns, RA ;
Hill, RP .
CANCER RESEARCH, 2004, 64 (06) :2054-2061
[8]   Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia [J].
Denny, WA ;
Wilson, WR .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (12) :2889-2901
[9]  
DENNY WA, 1996, BR J CANC S27, V74, P32
[10]   MUSCLE CRAMPING IN PHASE-I CLINICAL-TRIALS OF TIRAPAZAMINE (SR-4233) WITH AND WITHOUT RADIATION [J].
DOHERTY, N ;
HANCOCK, SL ;
KAYE, S ;
COLEMAN, CN ;
SHULMAN, L ;
MARQUEZ, C ;
MARISCAL, C ;
RAMPLING, R ;
SENAN, S ;
ROEMELING, RV .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (02) :379-382